Literature DB >> 17898596

Incomplete excision of basal cell carcinoma: a prospective trial.

Shirley Y Su1, Francesco Giorlando, Edmund W Ek, Tam Dieu.   

Abstract

BACKGROUND: As a measure of the standard of surgical care, incomplete excision of skin malignancy is an important clinical indicator, developed by the Royal Australasian College of Surgeons and the Australian Council on Healthcare Standards. Reported rates of incomplete excision of basal cell carcinoma vary widely (5 to 25 percent) among centers worldwide. This prospective study reports on the incidence of incomplete excision at a tertiary referral public hospital and determines the factors that may influence this.
METHODS: From January of 2001 to December of 2002, 1214 basal cell carcinomas were excised at Peter MacCallum Cancer Centre. Data were collected prospectively and analyzed using the FileMaker Pro program and SPSS software.
RESULTS: The overall percentage of incomplete excision was 11.2 percent for primary excisions. Risk factors for incomplete excision are the head site; morpheic, superficial, and infiltrative subtypes; lesions larger than 20 mm in diameter; the presence of multiple lesions; repair by skin graft; and recurrent and previously incompletely excised basal cell carcinomas. The type of anesthetic used did not affect outcome. There was no significant difference in the percentage of incomplete excision between consultants, registrars, and the clinical assistant, but this was probably attributable to the small number of cases performed by consultants at Peter MacCallum Cancer Centre.
CONCLUSIONS: This is the largest prospective study of incomplete excision of basal cell carcinomas. The authors' result is within the range reported in the current literature but is higher than anticipated. Preoperative "red-flagging" of basal cell carcinomas most at risk of incomplete excision may lead to a better result.

Entities:  

Mesh:

Year:  2007        PMID: 17898596     DOI: 10.1097/01.prs.0000279148.67766.e1

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  7 in total

1.  Staged-surgery with permanent pathology for the management of high-risk nonmelanoma skin cancer of the nose.

Authors:  Görkem Eskiizmir; Gülsüm Gençoğlan; Peyker Temiz; Zafer Hirçin; Aylin Ermertcan
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-08       Impact factor: 2.503

Review 2.  Basal Cell Carcinoma Surgery in general practice: Is there a role for the local General Practitioner?

Authors:  S H Keah; S C Ng
Journal:  Malays Fam Physician       Date:  2020-11-10

3.  Infiltrating basal cell carcinoma: a stellate peri-tumor dermatoscopy pattern as a clue to diagnosis.

Authors:  John H Pyne; Paul Fishburn; Anthony Dicker; Michael David
Journal:  Dermatol Pract Concept       Date:  2015-04-30

4.  Depth determination of skin cancers treated with superficial brachytherapy: ultrasound vs. histopathology.

Authors:  Rosa Ballester-Sánchez; Olga Pons-Llanas; Margarita Llavador-Ros; Rafael Botella-Estrada; Antonio Ballester-Cuñat; Alejandro Tormo-Micó; Francisco Javier Celadá-Álvarez; Silvia Rodríguez-Villalba; Manuel Santos-Ortega; Facundo Ballester-Pallarés; Jose Perez-Calatayud
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

Review 5.  Indication guidelines for Mohs micrographic surgery in skin tumors.

Authors:  Selma Schuartz Cernea; Gabriel Gontijo; Eugenio Raul de Almeida Pimentel; Roberto Gomes Tarlé; Glaysson Tassara; Juliana Areas de Souza Lima Beltrame Ferreira; Victor Miguel Coutinho Fernandes; Wanderley Marques Bernardo
Journal:  An Bras Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.896

6.  Clinicopathological Factors Associated with Incomplete Excision of High-risk Basal Cell Carcinoma.

Authors:  Hannah Ceder; Annie Ekström; Lajla Hadzic; John Paoli
Journal:  Acta Derm Venereol       Date:  2021-07-13       Impact factor: 3.875

7.  Pre-surgical high resolution ultrasound of facial basal cell carcinoma: correlation with histology.

Authors:  Francisco Bobadilla; Ximena Wortsman; Carla Muñoz; Laura Segovia; Miguel Espinoza; Gregor B E Jemec
Journal:  Cancer Imaging       Date:  2008-09-22       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.